Literature DB >> 18781977

CNS immune surveillance and neuroinflammation: endocannabinoids keep control.

Susanne A Wolf1, Svantje Tauber, Oliver Ullrich.   

Abstract

To avoid inflammatory escalation, the central nervous system (CNS) harbors an impressive arsenal of cellular and molecular mechanisms enabling strict control of immune reactions. We here summarize studies suggesting that the old paradigm of the "CNS immune privilege" is overly simplistic. The immune system is allowed to keep the CNS under surveillance, but in a strictly controlled, limited and well-regulated manner. The first line of defense lies outside the brain parenchyma to spare neuronal tissue from the detrimental effects of an inflammatory immune response. As a second line of defense neuroinflammation is unavoidable when pathogens infiltrate the brain or the CNS-immune-homeostasis fails. Inflammation in the CNS is often accompanied by divers brain pathologies. We here review recent strategies to maintain brain homeostasis and modulate neuroinflammation. We focus on Multiple Sclerosis as an example of a complex neuroinflammatory disease. In the past years, several in vitro, in vivo and clinical studies suggested that the endocannabinoid system participates crucially in the immune control and protection of the CNS. We discuss here the endocannabinoid system as a key regulator mechanism of the cross talk between brain and the immune system as well as its potential as a therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18781977     DOI: 10.2174/138161208785740090

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  16 in total

Review 1.  Functions of the CB1 and CB 2 receptors in neuroprotection at the level of the blood-brain barrier.

Authors:  Esmée Vendel; Elizabeth C M de Lange
Journal:  Neuromolecular Med       Date:  2014-06-15       Impact factor: 3.843

2.  A synthetic cannabinoid agonist promotes oligodendrogliogenesis during viral encephalitis in rats.

Authors:  Marylou V Solbrig; Yijun Fan; Neal Hermanowicz; Maria Grazia Morgese; Andrea Giuffrida
Journal:  Exp Neurol       Date:  2010-09-09       Impact factor: 5.330

3.  Peripheral endocannabinoid system dysregulation in first-episode psychosis.

Authors:  Miquel Bioque; Borja García-Bueno; Karina S Macdowell; Ana Meseguer; Pilar A Saiz; Mara Parellada; Ana Gonzalez-Pinto; Roberto Rodriguez-Jimenez; Antonio Lobo; Juan C Leza; Miguel Bernardo
Journal:  Neuropsychopharmacology       Date:  2013-07-04       Impact factor: 7.853

4.  Regulatory role of cannabinoid receptor 1 in stress-induced excitotoxicity and neuroinflammation.

Authors:  Silvia Zoppi; Beatriz G Pérez Nievas; José L M Madrigal; Jorge Manzanares; Juan C Leza; Borja García-Bueno
Journal:  Neuropsychopharmacology       Date:  2010-12-08       Impact factor: 7.853

5.  Cognitive dysfunction with aging and the role of inflammation.

Authors:  Arthur A Simen; Kelly A Bordner; Mark P Martin; Lawrence A Moy; Lisa C Barry
Journal:  Ther Adv Chronic Dis       Date:  2011-05       Impact factor: 5.091

6.  Regulatory role of the cannabinoid CB2 receptor in stress-induced neuroinflammation in mice.

Authors:  S Zoppi; J L Madrigal; J R Caso; M S García-Gutiérrez; J Manzanares; J C Leza; B García-Bueno
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

7.  Sex-dependent long-term effects of adolescent exposure to THC and/or MDMA on neuroinflammation and serotoninergic and cannabinoid systems in rats.

Authors:  Ana Belen Lopez-Rodriguez; Alvaro Llorente-Berzal; Luis M Garcia-Segura; Maria-Paz Viveros
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

8.  Impact of embedded endocannabinoids and their oxygenation by lipoxygenase on membrane properties.

Authors:  Enrico Dainese; Annalaura Sabatucci; Clotilde B Angelucci; Daniela Barsacchi; Marco Chiarini; Mauro Maccarrone
Journal:  ACS Chem Neurosci       Date:  2012-02-24       Impact factor: 4.418

9.  Anandamide inhibits Theiler's virus induced VCAM-1 in brain endothelial cells and reduces leukocyte transmigration in a model of blood brain barrier by activation of CB(1) receptors.

Authors:  Leyre Mestre; Paula M Iñigo; Miriam Mecha; Fernando G Correa; Miriam Hernangómez-Herrero; Frida Loría; Fabian Docagne; José Borrell; Carmen Guaza
Journal:  J Neuroinflammation       Date:  2011-08-18       Impact factor: 8.322

10.  Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors.

Authors:  Maria Teresa Cencioni; Valerio Chiurchiù; Giuseppina Catanzaro; Giovanna Borsellino; Giorgio Bernardi; Luca Battistini; Mauro Maccarrone
Journal:  PLoS One       Date:  2010-01-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.